Navigation Links
Positron Consolidates Radiopharmaceutical & Radioisotope Facilities

LUBBOCK, Texas, Aug. 7, 2012 /PRNewswire/ -- Positron Corporation (OTCBB:POSC) a leading molecular imaging healthcare company is pleased to announce the consolidation and integration of operations at the Crown Point, Indiana facility to its Lubbock, Texas site.

With the acquisition of Manhattan Isotope Technology (MIT), Positron gained the expertise, knowledge and radioactive materials facilities to manage all of the Company's radiopharmaceutical and radioisotope development, production, processing and distribution mission. Since the acquisition of MIT earlier this year, Positron has made significant developments in the production requirements of key PET radiopharmaceutical products, making the integration of production and facilities to the Lubbock facilities most favorable and advantageous for the Company.  MIT possesses the proper licenses, qualified staff, expertise, procedures and quality systems for all of Positron's pharmaceutical products.  The transfer of all records, systems and equipment was completed in late July.  The production of Indium Oxyquinoline will resume upon the modification of the Company's current Texas Radiation license to include Indium Oxine, with expected approval in August.

By locating all radioactive production to a single facility, Positron will simplify and improve regulatory compliance, radiation safety and quality procedures associated with the production of radioisotopes and radiopharmaceuticals. Additionally, this consolidation will significantly improve efficiencies, economics, and utilization throughout the company. "With this consolidation, Positron can better realize the potential of our radiochemical and radiopharmaceutical segments.  MIT will focus on key radioactive products allowing the company to accelerate and expand its offerings, while improving procedures and reducing operational costs. The integration and move to Lubbock will increase Positron's capabilities and further advance relationships with potential partners," said Patrick G. Rooney, CEO of Positron.

Jason Kitten, President of Manhattan Isotope Technology added, "the MIT staff brings the relevant experience in working with radioactive products and will continue with the production capabilities developed at Crown Point with indium and its target material cadmium.  Our team is excited at the opportunity to maximize and accelerate the expansion of all current and anticipated products."

About Positron: Positron Corporation is a leading molecular imaging healthcare company providing innovative nuclear medicine technologies and solutions that are reshaping the field of nuclear cardiology.  Through proprietary PET imaging systems, services and radiopharmaceutical solutions, Positron enables healthcare providers to more accurately diagnose disease and improve patient outcomes while practicing cost effective medicine.  Positron has gained significant traction in a diverse industry and continues their strong commitment to excellence and advancing cardiac imaging solutions.  More information about Positron is available at

Forward Looking Statements:  Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Positron assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.  Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.

SOURCE Positron Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ImaginAb and Singapore Radiopharmaceuticals Sign Master Service Agreement
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Smith & Nephew launches revolutionary open-architecture suture anchor for rotator cuff repair with greater pullout strength than competitors[i]
4. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
5. Biopharma M&A Trends Hold Steady, But Deals Declined in 2011
6. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
7. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
8. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
9. Ultra Clean to Present at the Jefferies 2012 Global Technology, Media & Telcom Conference
10. Axis Global Logistics Names Mr. Thomas Brennan, Vice President Strategic Accounts & Life Sciences
11. The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Gen-Probe Incorporated in Connection with the Sale of the Company to Hologic, Inc.
Post Your Comments:
(Date:11/26/2015)... November 26, 2015 Un nuevo ... Bremachlorin para el cáncer avanzado.   --> ... terapia fotodinámica de Bremachlorin para el cáncer avanzado. ... la inmunoterapia con la terapia fotodinámica de Bremachlorin para ... Research . --> Clinical Cancer Research . ...
(Date:11/26/2015)... , November 26, 2015 --> ... to use SyMRI to find optimal contrast weighting of MRI ... metastases, and has signed a research agreement with SyntheticMR in ... hospital. Using SyMRI, it is possible to generate multiple contrast ... after the patient has left, thus making it possible to ...
(Date:11/26/2015)... November 26, 2015 ... the "2016 Future Horizons and Growth ... Testing Market: Supplier Shares, Country Segment Forecasts, ... their offering. --> ) ... "2016 Future Horizons and Growth Strategies in ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... November 26, 2015 , ... ... to discuss bioavailability and the need to integrate dose form selection in early ... with OBN, the membership organization supporting and bringing together the UK’s emerging life ...
(Date:11/26/2015)... Aliso Viejo, CA (PRWEB) , ... November 26, ... ... X users a new set of retro-fused, self-animating trailer titles with ProTrailer: Vintage. ... custom style options. These classically-influenced trailer titles work with any font, giving users ...
(Date:11/25/2015)... ... November 25, 2015 , ... As part of a ... ™ attracts volunteers together who want to combine talents and resources to help ... in the process. The non-profit launched its first major fundraiser on November 6, ...
(Date:11/25/2015)... MN (PRWEB) , ... November 25, 2015 , ... ... launched offering factory direct sauna parts and accessories. , Sauna accessories help ... of the bather’s style and personality. From basic styles for the purist looking ...
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert is donating ... Beat ” campaign. The partnership between the two groups began in 2014 with Vitalalert ... cause. , MAP International was founded in 1954 and is an international Christian-based health ...
Breaking Medicine News(10 mins):